110 related articles for article (PubMed ID: 11965849)
1. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
[TBL] [Abstract][Full Text] [Related]
4. [Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin].
Queipo Zaragozá JA; Chicote Pérez F; Beltrán Meseguer JF; Borrell Palanca A; Giner Marco V; Esteve Claramunt J; Pastor Sempere F
Arch Esp Urol; 2004; 57(1):35-40. PubMed ID: 15112869
[TBL] [Abstract][Full Text] [Related]
5. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
6. Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin.
Mittelman M
Isr J Med Sci; 1996 Dec; 32(12):1201-6. PubMed ID: 9007154
[TBL] [Abstract][Full Text] [Related]
7. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors.
Steinmetz T; Hellmich M; Neise M; Aldaud A; Lerchenmüller C; Tsamaloukas A; Fandel F; Weiligmann C; Totzke U; Schmitz S
Oncologist; 2007 Jun; 12(6):748-55. PubMed ID: 17602064
[TBL] [Abstract][Full Text] [Related]
10. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
11. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
12. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in children undergoing chronic hemodialysis with recombinant human erythropoietin].
Rendo P; Biscigniano L; Turconi A; Sánchez Avalos JC; Greco J
Medicina (B Aires); 1994; 54(5 Pt 1):392-8. PubMed ID: 7658972
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
15. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
[TBL] [Abstract][Full Text] [Related]
17. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
